US Stock MarketDetailed Quotes
MGRM Monogram Orthopaedics
- 1.970
- -0.010-0.51%
Close Nov 22 16:00 ET
- 2.020
- +0.050+2.54%
Post 18:43 ET
67.60MMarket Cap-4291P/E (TTM)
2.040High1.960Low62.23KVolume1.980Open1.980Pre Close124.20KTurnover0.28%Turnover RatioLossP/E (Static)34.31MShares4.90052wk High3.89P/B43.97MFloat Cap1.53052wk Low--Dividend TTM22.32MShs Float48.990Historical High--Div YieldTTM4.04%Amplitude1.530Historical Low1.995Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Monogram Orthopaedics Stock Forum
3 MINUTES AGO, 8:31 AM EDT
VIA ACCESSWIRE
Monogram Technologies Announces Closing of Upsized and Oversubscribed $13 Million Public Offering
Monogram Technologies Inc. (NASDAQ:MGRM) has successfully closed its upsized and oversubscribed $13 million public offering of 8.00% Series D Convertible Cumulative Preferred Stock. The company sold 5,790,479 units, each comprising one share of Series D Preferred Stock and one common stock purchase warrant. The offering attracted 3,023 investors and provi...
Monogram Technologies Receives FDA Response for mBôs TKA System
Monogram Technologies (NASDAQ:MGRM) has received an Additional Information Request (AIR) from the FDA regarding its 510(k) premarket filing for the mBôs TKA System. The company has 180 days to respond or the application will be considered withdrawn. Monogram plans to conduct clinical trials to produce the required information.
CEO Ben Sexson stated that this response provides more clarity on the ...
Monogram Technologies Reports Second Quarter 2024 Financial Results
Monogram Technologies (NASDAQ:MGRM) reported its Q2 2024 financial results, highlighting key operational achievements.
The company submitted a 510(k) premarket filing to the FDA for its mBôs TKA System, which passed the administrative review.
Monogram also secured a strategic collaboration with Shalby for multicenter clinical trials in India.
Financial results showed R&D expenses decrea...
Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration
Monogram Technologies Inc. (NASDAQ:MGRM) has announced a strategic collaboration with Shalby (NSE:SHALBY) to conduct a multicenter clinical trial for its mBȏs TKA System. Shalby, the world's largest orthopedic hospital chain, will enroll patients at various sites in India to evaluate the system's safety and effectiveness. This collaboration follows Monogram's recent 510(k) submissio...
Monogram Technologies Submits 510(k) Application for MBôs TKA System Clearance
Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review
FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested
No comment yet